The *GBA1* p.E427K (p.E388K) Variant is a Risk Factor for Synucleinopathies: A Meta-Analysis

Leah V. Chifamba, MSc,[1,2] Sitki Cem Parlar, MSc,[1,2] Emma N. Somerville, BSc,[1,2] Lang Liu, MSc,[1,2] Eric Yu, PhD,[1,2] Farnaz Asayesh, MSc,[1,3] Jamil Ahmad, PhD,[1,3] Meron Teferra, MSc,[1,3] Jennifer A. Ruskey, MSc,[1,3] Cheryl Waters, MD,[4] Oury Monchi, PhD,[3,5,6] Yves Dauvilliers, MD, PhD,[7] Nicolas Dupré, MD, FRCP,[8,9] Alla Timofeeva, MD, PhD,[10] Anton Emelyanov, PhD,[10] Sofya Pchelina DSci,[10] Irina Miliukhina, MD, PhD,[11] Lior Greenbaum, MD,[12,13] Sharon Hassin-Baer, MD,[13] Orly Goldstein, PhD,[14] Mandy Radefeldt, MSc,[15] Peter Bauer, MD,[15] Christian Beetz, PhD,[15] Allison A. Dilliott, PhD,[16] James C. Beck, PhD,[16] Konstantin Senkevich, MD, PhD,[1,2,17] The ROPAD Study Group, The Parkinson's Foundation PD GENEration Study, Christine Klein, MD,[18] Roy N. Alcalay, MD, MSc,[4,19,20] Ziv Gan-Or, MD, PhD[1,2,3,21]

Affiliations:

1. The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Quebec, Canada

2. Department of Human Genetics, McGill University, Montréal, Quebec, Canada

3. Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada

4. Department of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, USA

5. Centre de recherche de l'Institut universitaire de gériatrie de Montréal, Montréal, Quebec, Canada

6. Département de radiologie, radio-oncologie et médecine nucléaire, Université de Montréal, Montréal, Quebec, Canada

7. National Reference Center for Narcolepsy, Sleep Unit, Department of Neurology, Guide-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France

8. Neuroscience Axis, CHU de Québec–Université Laval, Quebec City, QC, Canada

9. Department of Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada

10. First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia

11. Institute of the Human Brain of the Russian Academy of Sciences, Saint Petersburg, Russia

12. The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

13. Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

14. Laboratory of Biomarkers and Genomics of Neurodegeneration, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

15. CENTOGENE GmbH, Am Strande 7, 18055 Rostock, Germany

16. Parkinson's Foundation, New York, NY, USA

17. Department of Specialized Medicine, Division of Medical Genetics, McGill University Health Centre, Montreal, Quebec, Canada

18. Institute of Neurogenetics and Department of Neurology, University of Lübeck and University Hospital Schleswig-Holstein, Lübeck, Germany

19. The Movement Disorders Institute, Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel

20. Division of Movement Disorders, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

21. Quantitative Life Sciences, McGill University, Montréal, Quebec, Canada

Corresponding author:
Ziv Gan-Or
Montreal Neurological Institute
McGill University
1033 Pine Avenue, West
Ludmer Pavilion, room 312
Montréal, QC, H3A 1A1
Phone: +1-514-398-5845
Email: ziv.gan-or@mcgill.ca

Word count: 1,696

Relevant conflicts of interest/financial disclosures: Z.G.-O. has received consulting fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Neuron23, Handl Therapeutics, UCB, Ono Therapeutics, Denali, Bial Biotech, Capsida, Takeda, Simcere, EG427, Jazz Pharmaceuticals, Guidepoint, Lighthouse, and Deerfield. CK has

received consulting fees from Centogene and Biogen, speakers' honoraria from Bial, and royalties from Oxford University Press and Springer Nature.

Funding agencies: This study was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. The Columbia University cohort is supported by the Parkinson's Foundation, the National Institutes of Health (K02NS080915 and UL1TR000040) and the Brookdale Foundation. We also recognize the contributions of the G-Can (GBA1-Canada) Initiative, an open-science partnership focused on research into GBA1-related neurodegeneration. G-Can receives support from the Galen and Hilary Weston Foundation, the Silverstein Foundation, and J. Sebastian van Berkom and Ghislaine Saucier

Abstract

Background

Variants in *GBA1* are important genetic risk factors for synucleinopathies, including Parkinson's disease (PD). While several *GBA1* variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear.

Objective

To determine whether the *GBA1* p.E427K variant is associated with risk of synucleinopathies.

Methods

We performed a meta-analysis of case-control studies reporting the frequency of *GBA1* p.E427K (p.E388K) in PD and related synucleinopathies. Data were obtained from published studies, open-access resources, and large cohorts, including in-house datasets. Odds ratios (ORs) were calculated for each cohort and pooled using a random-effects model.

Results

Across 67,484 patients and 124,079 controls, *GBA1* p.E427K was associated with increased disease risk (pooled OR = 1.87, 95% CI 1.28–2.72, P = 0.001). Enzymatic data showed reduced glucocerebrosidase activity in carriers.

Conclusions

The *GBA1* p.E427K variant is a risk factor for synucleinopathies and should be considered in genetic studies and clinical trials.

Introduction

GBA1 variants are important genetic risk factors for synucleinopathies and are found in approximately 5-33% of patients with Parkinson's disease (PD), dementia with Lewy bodies (DLB), or the prodromal condition rapid eye movement (REM) sleep behavior disorder (RBD) (1−3). Given their high prevalence, clinical trials are currently recruiting individuals with *GBA1* variants, with additional trials planned in the future (4).

The classification of *GBA1* variants is critical for such trials, as different types of *GBA1* variants may be associated with distinct rates of disease progression (5). Based on their phenotypic effects in homozygous state in Gaucher disease (GD), *GBA1* variants can be classified as *mild* if they cause GD type 1, or *severe* if they cause GD types 2 or 3 (6). An additional category includes *GBA1* variants that do not cause GD but are associated with an increased risk of PD, and these are classified as *risk variants* (6). Carriers of severe *GBA1* variants have an earlier age at onset and experience more rapid progression of both motor and non-motor symptoms (7). Therefore, to ensure balanced progression rates in clinical trial arms, an equal distribution of severe, mild and risk *GBA1* variants across treatment and placebo groups is required.

Currently, three *GBA1* variants are reliably classified as risk factors: p.E365K (p.E326K), p.T408M (p.T369M) (8), and the African-specific intronic splicing variant rs3115534-G (9). Another variant, p.E427K (p.E388K), has been proposed as a risk factor for PD (1). However, this association has not been confirmed by robust genetic analyses. Consequently, carriers of p.E427K were not included in the first two phase 2 clinical trials targeting PD patients with *GBA1* variants (https://clinicaltrials.gov/study/NCT05819359) (10).

In the present study, we evaluated the role of *GBA1* p.E427K in synucleinopathies using data from 67,484 patients and 124,079 controls across multiple cohorts, followed by a meta-analysis of effects across cohorts.

Subjects and Methods

Data sources and cohorts

We identified published case-control studies reporting genotyping data for *GBA1* p.E427K (also termed p.E388K, rs149171124) variant in PD cohorts using the GBA1-PD browser (6) (accessed October 2025). Studies were eligible for inclusion if they reported the number of p.E427K carriers among PD cases and controls. Studies without available carrier counts or with overlapping cohorts were excluded. Using these criteria, seven studies were included (12,442 PD cases and 6,001 controls) (Table 1).

Additional data were obtained from several cohorts, including: (i) In-house McGill University cohorts comprising 7,111 PD patients, 2,800 RBD patients and 5,493 controls. The cohorts were recruited in Quebec, Canada and Montpellier, France (11), Columbia University, New York (12), Sheba Medical Center, Israel (13) and Pavlov First State Medical University and the Institute of Human Brain, Russia (14). (ii) the Centogene - Rostock International Parkinson's Disease Study (ROPAD) (15), comprising 20,102 patients with PD and 35,134 controls (16); (iii) the PD GENEration (17) with 25,932 PD patients and no available control group, therefore, this cohort was not included in the meta-analysis; (iv) Accelerated Medicines Partnership - Parkinson's Disease (AMP-PD) (https://amp-pd.org/), including 1,820 PD, 2,605 DLB cases and 4,718 controls; (v) the UK Biobank (UKBB) (https://www.ukbiobank.ac.uk/), with 2,606 PD patients and 56,973 controls; and (vi) data from Global Parkinson's Genetics Program (GP2)

(18), consisting of 17,998 cases and 15,760 controls, obtained from the publicly available browser, (https://gp2.broadinstitute.org/) (18).

Genetic sequencing and quality control

Targeted next-generation sequencing of *GBA1* in the McGill University cohorts was performed using molecular inversion probes, as previously described (19). Sequencing was conducted at the McGill Genome Center using the Illumina NovaSeq 6000 SP PE100 platform. Reads were aligned to the hg19 reference genome using the Burrows-Wheeler Aligner, and post-alignment processing and variant calling were performed with Genome Analysis Toolkit (GATK v3.8). Quality control (QC) was carried out using PLINK v1.9 (20), excluding variants with missingness of >10%, genotype quality (GQ) < 30, or sequencing depth < 30x.

Whole-genome sequencing (WGS) data for the AMP-PD and UKBB cohorts were obtained from Terra platform (https://app.terra.bio/) and UKBB Research Analysis Platform (https://www.ukbiobank.ac.uk/) respectively. AMP-PD data underwent sample and variant-level QC as previously described (21), while UK Biobank WGS data were processed using GATK v3.8, applying a minimum sequencing depth coverage of 30x and GQ ≥20. The hg38 reference genome was used for both AMP-PD and UK Biobank datasets.

For Global Parkinson's Genetics Program (GP2), variant carrier counts for *GBA1* p.E427K were obtained from the GP2 Genome Browser (18), an open-access resource aggregating harmonized summary-level genotyping data from multiple contributing cohorts, using the most recent version (September 2025). Only summary-level data were accessed, and no individual-level sequencing data or additional QC procedures were performed by the authors.

GBA1 p.E427K variant data from the Centogene ROPAD cohort were generated using panel sequencing, whole-exome sequencing (WES), and/or WGS, as previously described (16).

Similarly, PD GENEration cohort data were sequenced using WES and WGS (17). In both cohorts, processed, high-quality variant calls were provided by the respective study teams, and no additional sequencing or QC procedures were performed in the present study. All participating institutions received institutional review board approval, and all participants provided written informed consent.

Variant definition

The *GBA1* p.E427K is referred to using the nomenclature including the 39-amino acid signal peptide of glucocerebrosidase. The alternative nomenclature p.E388K, which excludes the signal peptide, is provided in parentheses where relevant. All cohorts were harmonized to this nomenclature prior to statistical analysis.

Meta-analysis

All cohorts included in the meta-analysis provided carrier counts for both cases and controls. For each study and cohort, a 2×2 contingency table was constructed comparing the number of carriers of *GBA1* p.E427K among patients with synucleinopathies and controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated from these tables. The standard error of the log(OR) was derived using the inverse variance method. To account for variability across studies, pooled effect estimates were obtained using a random-effects model. Between-study heterogeneity was assessed using Cochran's Q statistic and quantified with the I^2 index. A constant continuity correction of 0.5 was applied in studies or cohorts where zero counts were present in either the case or control arm, allowing OR calculations. Forest plots were generated in Python using the matplotlib package (22).

Results

We examined the association between *GBA1* p.E427K and synucleinopathies across all included studies and cohorts using a random-effects meta-analysis (Figure 1A). In the pooled analysis, carriage of *GBA1* p.E427K was associated with an increased risk of synucleinopathies (pooled OR = 1.87, 95% CI = 1.28–2.72, P = 0.001). There was no evidence of between study heterogeneity (Q = 9.20, degrees of freedom [df] = 15, P = 0.87; I² = 0%). We repeated the analysis without the data from GP2 in case there is sample overlap with ROPAD or other studies and received similar results (Figure 1B). Glucocerebrosidase enzymatic activity data were available for 11 heterozygous p.E427K carriers from Centogene and were, on average, 32% lower than in non-carriers (p = 0.0015).

In addition to the case-control datasets included in the meta-analysis, we examined the frequency and ethnicity of *GBA1* p.E427K in the PD GENEration cohort, a large independent case-only sequencing dataset. Among 25,932 individuals with PD, 13 heterozygous carriers of *GBA1* p.E427K were identified, including individuals of European, Hispanic/Latino, Black and Ashkenazi Jewish ancestries, suggesting that this variant is relevant across multiple populations. Indeed, in gnomAD (https://gnomad.broadinstitute.org/), this variant is reported with similar frequencies in Europeans and South Asians, with lower frequencies in Finnish Europeans, Admixed Americans, and African/African American.

Discussion

In the current study, analysing a total of 67,484 patients and 124,079 controls from the literature, open-access resources, and in-house cohorts, we demonstrate that the *GBA1* p.E427K is a risk factor for synucleinopathies, with an effect size comparable to that of the three other established PD risk variants, p.E365K, p.T408M and rs3115534.

Similar to p.E365K, which has an estimated OR for PD risk of 1.8–2.0 (23), and p.T408M, which has an OR of 1.7–1.9 (8,23), the OR for p.E427K in our meta-analysis was ~1.8. Since p.E427K is less frequent than p.E365K and p.T408M in the general population (allele frequency in Europeans in gnomAD of 0.0002 vs. 0.013 and 0.008, respectively), which explains why previous studies examining this variant were underpowered to detect an association with PD (23). The reduction of GCase activity in the 11 samples available from Centogene is comparable to that reported for carriers of p.E365K and p.T408M (24), further supporting p.E427K as a PD risk variant.

One PD patient in our study was homozygous for the *GBA1* p.E427K variant and, in their early 60s, exhibited no signs or symptoms of GD. This individual had mildly elevated lyso-Gb1 (glucosylsphingosine) levels (9.7 ng/ml) compared with controls (4–7 ng/ml), but substantially lower than levels typically observed in GD patients (>20 ng/ml, often >100 ng/ml). A previous study identified two sisters who were compound heterozygous for *GBA1* p.N409S/p.E427K and reported that both were asymptomatic, although they were very young at the time of evaluation (25). One study of Colombian GD patients reported an individual homozygous for the p.E427K variant. However, this report cites another Colombian study (26), as having identified the same variant in Colombian patients with PD, which is not the case. That study did not report the presence of this variant. Therefore, the purported association between homozygous *GBA1*

p.E427K and GD should be interpreted with caution. Based on the currently available data, there is no reliable evidence that this variant causes GD. Moreover, given the variant's frequency in European populations (~0.0002), one would expect to observe GD patients homozygous for this variant if it were pathogenic, particularly since much rarer variants, such as p.L483P and others, have been reported repeatedly in patients with GD (27).

A key limitation of this study is the small number of variant carriers within individual cohorts, often ranging from 0–5 per study arm. As a result, single-cohort effect estimates may be unstable and highly sensitive to minor differences in QC or ancestry classification. Although a random-effects meta-analysis model was applied to account for between-study variability, effect sizes from individual cohorts should be interpreted with caution. The pooled meta-analytic estimate therefore represents the most reliable and appropriate reference for inference, rather than any single-study result.

In conclusion, our study demonstrates that *GBA1* p.E427K is a risk factor for synucleinopathies. Accordingly, carriers of this variant can be included in clinical studies and therapeutic trials in a manner similar to carriers of the established *GBA1* risk variants p.E365K and p.T408M.

Acknowledgments

We acknowledge the participants from the contributing cohorts whose involvement made this study possible. This work was supported in part by the Canada First Research Excellence Fund through McGill University's Healthy Brains, Healthy Lives initiative, with additional computational support from Calcul Québec and Compute Canada. Z.G.-O. receives support from the Fonds de Recherche du Québec–Santé through the Chercheurs-Boursiers Award, in

partnership with Parkinson Quebec, and holds a William Dawson Scholar appointment. Participant recruitment for this study was facilitated in part by the Quebec Parkinson's Network (http://rpq-qpn.ca/en/). Access to UK Biobank data was enabled by the NeuroHub infrastructure under Application Number 45551 and was undertaken thanks in part to funding from the Canada First Research Excellence Fund. Which was awarded through the Healthy Brains, Healthy Lives initiative at McGill University, and was enabled in part by support provided by Calcul Québec and the Digital Research Alliance of Canada. Furthermore, data used in this article was also obtained in January 2023 from the Accelerating Medicines Partnership® (AMP®) Parkinson's Disease (AMP PD) Knowledge Platform, release 2.5. More recent releases have since become available. For the latest updates on AMP-PD, please visit https://www.amp-pd.org. The AMP® PD program is a public-private partnership managed by the Foundation for the National Institutes of Health and funded by the National Institute of Neurological Disorders and Stroke (NINDS) in partnership with the Aligning Science Across Parkinson's (ASAP) initiative; Celgene Corporation, a subsidiary of Bristol-Myers Squibb Company; GlaxoSmithKline plc (GSK); The Michael J. Fox Foundation for Parkinson's Research ; Pfizer Inc.; AbbVie Inc.; Sanofi US Services Inc.; and Verily Life Sciences.

Additional Data used in the preparation of this article were obtained from the Parkinson's Foundation PD GENEration study. PD GENEration is a flagship initiative of the Parkinson's Foundation in partnership with Aligning Science Across Parkinson's (ASAP) and the Global Parkinson's Genetics Program (GP2). Additional financial and in-kind support comes from the Parkinson's community - industry partners, nonprofit organizations, and individuals whose lives

have been touched by Parkinson's. For up-to-date information on the study, visit

https://www.parkinson.org/pdgeneration.

Author Roles

(1) Research Project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the First Draft, B. Review and Critique.

L.V.C.: 1A, 1B, 1C, 2A, 2B, 3A

S.C.P.: 2A, 2B, 3B

E.N.S.:2B, 3B

L.L.:2B, 3B

E.Y.:2B,3B

F.A.:2B,3B

M.T.: 2B,3B

J.A.:2B,3B

J.A.R.: 2B,3B

C.W.: 2B,3B

O.M.:2B,3B

Y.D.:2B,3B

N.D.:2B,3B

A.T.:2B,3B

A.E.:2B,3B

S.P.:2B,3B

I.M.:2B,3B

L.G.:2B,3B

S.H.B.:2B,3B

R.N.A.:2B,3B

M.R.:2B, 3B

P.B.:2B, 3B

C.B.:2B, 3B.

C.K.: 2B, 3B

A.A.D.:2B, 3B

J.C.B.:2B, 3B

K.S.: 2B, 2C, 3B

Z.G.O.: 1A, 1B, 2A, 3B

Data Availability Statement

All data generated in this study, including the variants analyzed, are available within the main manuscript. The analysis code is publicly accessible at https://github.com/gan-orlab/GBA-p.E388K-Meta-analysis. Portions of the McGill cohorts are available through the Canadian Open Parkinson Network (C-OPN), with access to genetic and related data granted upon request and approval by the C-OPN data access committee (https://copn-rpco.ca/submit-a-request/). AMP-PD data were accessed and analyzed via the Terra platform (https://amp-pd.org/), and UK Biobank data were obtained as whole-genome sequencing datasets through the UK Biobank Research Analysis Platform (https://www.ukbiobank.ac.uk/).

References

1. Huh YE, Usnich T, Scherzer CR, Klein C, Chung SJ. GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy. J Mov Disord. 2023 Sep;16(3):261–78. doi:10.14802/jmd.23023 PubMed PMID: 37302978; PubMed Central PMCID: PMC10548077.

2. Krohn L, Ruskey JA, Rudakou U, Leveille E, Asayesh F, Hu MTM, et al. GBA variants in REM sleep behavior disorder: A multicenter study. Neurology. 2020 Aug 25;95(8):e1008–16. doi:10.1212/WNL.0000000000010042 PubMed PMID: 32591474; PubMed Central PMCID: PMC7668554.

3. Bougea A. Underlying Mechanisms of GBA1 in Parkinson's Disease and Dementia with Lewy Bodies: Narrative Review. Genes. 2025 Dec 15;16(12):1496. doi:10.3390/genes16121496 PubMed PMID: 41465169; PubMed Central PMCID: PMC12732524.

4. Menozzi E, Del Pozo SL, Macnaughtan J, Mezabrovschi R, Koletsi S, Mitrotti P, et al. Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials. Npj Park Dis. 2025 Oct 1;11(1):281. doi:10.1038/s41531-025-01063-3

5. Gan-Or Z. Clinical genetic testing in Parkinson's disease should become part of routine patient care. Brain. 2024 Aug 1;147(8):2595–7. doi:10.1093/brain/awae181 PubMed PMID: 39087915; PubMed Central PMCID: PMC11292891.

6. Parlar SC, Grenn FP, Kim JJ, Baluwendraat C, Gan-Or Z. Classification of GBA1 variants in Parkinson's disease; the GBA1-PD browser. Mov Disord Off J Mov Disord Soc. 2023 Mar;38(3):489–95. doi:10.1002/mds.29314 PubMed PMID: 36598340; PubMed Central PMCID: PMC10033371.

7. Ren J, Zhan X, Zhou H, Guo Z, Xing Y, Yin H, et al. Comparing the effects of GBA variants and onset age on clinical features and progression in Parkinson's disease. CNS Neurosci Ther. 2024;30(2):e14387. doi:10.1111/cns.14387

8. Mallett V, Ross JP, Alcalay RN, Ambalavanan A, Sidransky E, Dion PA, et al. GBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis. Neurol Genet. 2016 Oct;2(5):e104. doi:10.1212/NXG.0000000000000104 PubMed PMID: 27648471; PubMed Central PMCID: PMC5017539.

9. Rizig M, Bandres-Ciga S, Makarious MB, Ojo OO, Crea PW, Abiodun OV, et al. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 2023 Nov 1;22(11):1015–25. doi:10.1016/S1474-4422(23)00283-1 PubMed PMID: 37633302.

10. Giladi N, Alcalay RN, Cutter G, Gasser T, Gurevich T, Höglinger GU, et al. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre,

double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2023 Aug;22(8):661–71. doi:10.1016/S1474-4422(23)00205-3 PubMed PMID: 37479372.

11. Gan-Or Z, Rao T, Leveille E, Degroot C, Chouinard S, Cicchetti F, et al. The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. J Park Dis. 2020 Jan 1;10(1):301–13. doi:10.3233/JPD-191775

12. Alcalay RN, Levy OA, Wolf P, Oliva P, Zhang XK, Waters CH, et al. SCARB2 variants and glucocerebrosidase activity in Parkinson's disease. Npj Park Dis. 2016 Mar 10;2(1):1. doi:10.1038/npjparkd.2016.4

13. Ruskey JA, Greenbaum L, Roncière L, Alam A, Spiegelman D, Liong C, et al. Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. Eur J Med Genet. 2019 Jan;62(1):65–9. doi:10.1016/j.ejmg.2018.05.005 PubMed PMID: 29842932; PubMed Central PMCID: PMC6261782.

14. Senkevich K, Beletskaia M, Dworkind A, Yu E, Ahmad J, Ruskey JA, et al. Association of Rare Variants in ARSA with Parkinson's Disease. Mov Disord Off J Mov Disord Soc. 2023 Oct;38(10):1806–12. doi:10.1002/mds.29521 PubMed PMID: 37381728; PubMed Central PMCID: PMC10615669.

15. Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt EJ, Laabs BH, et al. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study. Brain J Neurol. 2024 Aug 1;147(8):2652–67. doi:10.1093/brain/awae188 PubMed PMID: 39087914; PubMed Central PMCID: PMC11292909.

16. Radefeldt M, Lemke S, Chaichoompu K, Paul JJ, Curado F, Valzania F, et al. Genetic and Epidemiological Insights into RAB32-Linked Parkinson's Disease. Mov Disord Off J Mov Disord Soc. 2025 Jan;40(1):147–51. doi:10.1002/mds.30041 PubMed PMID: 39460989; PubMed Central PMCID: PMC11752972.

17. Cook L, Verbrugge J, Schwantes-An TH, Schulze J, Foroud T, Hall A, et al. Parkinson's disease variant detection and disclosure: PD GENEration, a North American study. Brain J Neurol. 2024 Aug 1;147(8):2668–79. doi:10.1093/brain/awae142 PubMed PMID: 39074992; PubMed Central PMCID: PMC11292896.

18. Fang ZH, Grant RH, Vitale D, Hernandez CF, Hong S, Leonard HL, et al. The Global Parkinson's Disease Genetics (GP2) Genome Browser. medRxiv. 2025 Dec 31;2025.12.29.25343143. doi:10.64898/2025.12.29.25343143 PubMed PMID: 41503486; PubMed Central PMCID: PMC12772649.

19. Rudakou U, Ruskey JA, Krohn L, Laurent SB, Spiegelman D, Greenbaum L, et al. Analysis of common and rare VPS13C variants in late-onset Parkinson disease. Neurol Genet. 2020 Jan 9;6(1):385. doi:10.1212/NXG.0000000000000385 PubMed PMID: 32042909; PubMed Central PMCID: PMC6984134.

20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum

Genet. 2007 Sep;81(3):559–75. doi:10.1086/519795 PubMed PMID: 17701901; PubMed Central PMCID: PMC1950838.

21. Iwaki H, Leonard HL, Makarious MB, Bookman M, Landin B, Vismer D, et al. Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource. Mov Disord. 2021;36(8):1795–804. doi:10.1002/mds.28549

22. Hunter JD. Matplotlib: A 2D Graphics Environment. Comput Sci Eng. 2007 May;9(3):90–5. doi:10.1109/MCSE.2007.55

23. Zhang Y, Shu L, Sun Q, Zhou X, Pan H, Guo J, et al. Integrated Genetic Analysis of Racial Differences of Common GBA Variants in Parkinson's Disease: A Meta-Analysis. Front Mol Neurosci. 2018;11:43. doi:10.3389/fnmol.2018.00043 PubMed PMID: 29527153; PubMed Central PMCID: PMC5829555.

24. Alcalay RN, Levy OA, Waters CC, Fahn S, Ford B, Kuo SH, et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain J Neurol. 2015 Sep;138(Pt 9):2648–58. doi:10.1093/brain/awv179 PubMed PMID: 26117366; PubMed Central PMCID: PMC4564023.

25. Paciotti S, Persichetti E, Pagliardini S, Deganuto M, Rosano C, Balducci C, et al. First pilot newborn screening for four lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene. Clin Chim Acta Int J Clin Chem. 2012 Nov 20;413(23–24):1827–31. doi:10.1016/j.cca.2012.07.011 PubMed PMID: 22820396.

26. Pomponio RJ, Cabrera-Salazar MA, Echeverri OY, Miller G, Barrera LA. Gaucher disease in Colombia: mutation identification and comparison to other Hispanic populations. Mol Genet Metab. 2005 Dec;86(4):466–72. doi:10.1016/j.ymgme.2005.07.026 PubMed PMID: 16185907.

27. Davies EH, Mengel E, Tylki-Szymanska A, Kleinotiene G, Reinke J, Vellodi A. Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool. J Inherit Metab Dis. 2011 Oct;34(5):1053–9. doi:10.1007/s10545-011-9347-z PubMed PMID: 21626202.

28. Asselta R, Rimoldi V, Siri C, Cilia R, Guella I, Tesei S, et al. Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism Relat Disord. 2014 Nov;20(11):1215–20. doi:10.1016/j.parkreldis.2014.09.003 PubMed PMID: 25249066; PubMed Central PMCID: PMC4228056.

29. Benitez BA, Davis AA, Jin SC, Ibanez L, Ortega-Cubero S, Pastor P, et al. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease. Mol Neurodegener. 2016 Apr 19;11:29. doi:10.1186/s13024-016-0097-0 PubMed PMID: 27094865; PubMed Central PMCID: PMC4837564.

30. den Heijer JM, Cullen VC, Quadri M, Schmitz A, Hilt DC, Lansbury P, et al. A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands. Mov Disord Off J

Mov Disord Soc. 2020 Sep;35(9):1667–74. doi:10.1002/mds.28112 PubMed PMID: 32618053; PubMed Central PMCID: PMC7540512.

31. Duran R, Mencacci NE, Angeli AV, Shoai M, Deas E, Houlden H, et al. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov Disord Off J Mov Disord Soc. 2013 Feb;28(2):232–6. doi:10.1002/mds.25248 PubMed PMID: 23225227; PubMed Central PMCID: PMC4208290.

32. Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet. 2011 Jan 1;20(1):202–10. doi:10.1093/hmg/ddq454 PubMed PMID: 20947659.

33. Velez-Pardo C, Lorenzo-Betancor O, Jimenez-Del-Rio M, Moreno S, Lopera F, Cornejo-Olivas M, et al. The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru. Parkinsonism Relat Disord. 2019 Jun;63:204–8. doi:10.1016/j.parkreldis.2019.01.030 PubMed PMID: 30765263; PubMed Central PMCID: PMC7175776.

34. Zhao Y wen, Pan H xu, Liu Z, Wang Y, Zeng Q, Fang Z huan, et al. The Association Between Lysosomal Storage Disorder Genes and Parkinson's Disease: A Large Cohort Study in Chinese Mainland Population. Front Aging Neurosci. 2021 Nov 15;13. doi:10.3389/fnagi.2021.749109

Figure 1A: Forest plot of studies with available case control data on the *GBA1* p.E388K variant across cohorts.

RE, random effects; PD, Parkinson's disease; DLB, dementia with Lewy bodies; RBD, rapid eye movement sleep behavior disorder; UKBB, UK Biobank; AMP-PD, Accelerating Medicines Partnership–Parkinson's Disease; GP2, Global Parkinson's Genetics Program; ROPAD, Rostock International Parkinson's Disease Study; N, number of individuals

Figure 1B: Forest plot of studies with available case control data on the *GBA1* p.E388K variant across cohorts without GP2 cohorts.

RE, random effects; PD, Parkinson's disease; DLB, dementia with Lewy bodies; RBD, rapid eye movement sleep behavior disorder; UKBB, UK Biobank; AMP-PD, Accelerating Medicines Partnership–Parkinson's Disease; ROPAD, Rostock International Parkinson's Disease Study; N, number of individuals

Table 1: Distribution of *GBA1* p.E388K carriers across cohorts included in the meta-analysis

Cohort	Synucleinopathy	Carriers Cases	Carriers Controls	Total Cases	Total Controls
Parkinson Institute Biobank (28)	PD	5	1	2,766	1,111
European-American (29)	PD	1	0	478	337
Dutch (30)	PD	3	0	3,402	655
Not specified (31)	PD	1	0	185	257
European (32)	PD	1	0	1,130	391
Colombian and Perusian (33)	PD	0	1	602	319
Chinese (34)	PD	1	0	3,879	2,931
AMP-PD	DLB	2	0	2,605	1,894
AMP-PD	PD	1	2	1,820	2,824
Centogene (ROPAD)	PD	30	21	20,102	35,134
GP2	PD	6	5	17,998	15,760
McGill	PD	10	3	7,111	5,493[1]
McGill	RBD	2	3	2,800	5,493
UKBB	PD	2	19	2,606	56,973
Total		65	52	67,484	124,079

PD, Parkinson's disease; DLB, dementia with Lewy bodies; RBD, rapid eye movement sleep behavior disorder; UKBB, UK Biobank; AMP-PD, Accelerating Medicines Partnership–Parkinson's Disease; GP2, Global Parkinson's Genetics Program; ROPAD, Rostock International Parkinson's Disease Study; N, number of individuals

---

[1] McGill controls (N=5,493) are shared between the McGill PD and McGill RBD comparisons; controls were counted once in the overall totals